Article Text

PDF

A meta-analysis of positive airway pressure treatment for cardiovascular prevention: why mix apples and pears?
  1. Yüksel Peker1,2,3,
  2. Patrick J Strollo Jr3,4
  1. 1 Department of Pulmonary Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey
  2. 2 Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  3. 3 Division of Pulmonary, Allergy, and Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  4. 4 VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA
  1. Correspondence to Professor Yüksel Peker, Department of Pulmonary Medicine, Faculty of Medicine, Marmara University, Pendik Education and Research Hospital, Sleep Medicine Center, Pendik, Istanbul, Turkey; yuksel.peker{at}marmara.edu.tr

Statistics from Altmetric.com

Commentary on: Yu J, Zhou Z, McEvoy RD, et al. Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea: a systematic review and meta-analysis. JAMA 2017;318:156–66.

Context

Despite an increasing body of evidence supporting an independent association between sleep apnoea and cardiovascular outcomes, there is still a lack of convincing data to suggest that treating this disorder reduces the cardiovascular risk. Sleep apnoea may be either obstructive (OSA) or central (CSA), or of a combination of both types, especially in patients with concomitant cardiovascular disease (CVD). Randomised controlled trials (RCT) have shown that continuous positive airway pressure (CPAP) treatment reduces excessive daytime sleepiness and improves quality of life in sleepy patients with OSA.1 Randomisation of patients with this phenotype to no treatment has been considered unethical. Thus, the long-term RCTs during the last decade have been focused on asymptomatic or minimally symptomatic patients with OSA. Positive airway pressure (PAP) for patients with CSA with adaptive servo-ventilation (ASV) has also been targeted.

Methods

This review and meta-analysis included data from 10 RCTs (nine CPAP; one ASV) for patients with sleep apnoea (n=7266; mean age, 61 years; 81% men), after identification of 5765 records through EMBASE, MEDLINE and Cochrane Library and after extracting data using standardised forms. Summary relative risks (RRs), risk differences (RDs) and 95% CI were obtained using random effects meta-analysis. The main outcomes were a composite of major adverse cardiovascular events (MACEs) including acute coronary syndrome (ACS) events, stroke or vascular death as well as cause-specific vascular events and all-cause death.

Findings

Among 356 MACEs and 613 deaths recorded, the authors found no significant association of PAP neither with MACEs (RR 0.77; 95% CI 0.53 to 1.13 and RD −0.01; 95% CI −0.03 to 0.01) nor with cardiovascular death (RR 1.15; 95% CI 0.88 to 1.50), all-cause death (RR 1.13; 95% CI 0.99 to 1.29), ACS (RR 1.00; 95% CI 0.65 to 1.55), stroke (RR 0.90; 95% CI 0.92 to 1.21) and heart failure (RR 1.03; 95% CI 0.92 to 1.16). Meta-regressions failed to identify any significant association of PAP with outcomes for different levels of apnoea severity, follow-up duration or adherence to PAP (all P values >0.13).

Commentary

The current meta-analysis is unfortunately compromised by a rather heterogeneous and inappropriate group of studies that included sleep clinic2 3 as well as cardiac4–8 and cerebrovascular cohorts.6 8 Studies that examined primarily OSA2 3 6–8 and CSA4 5 were included. This may be problematic since OSA is considered to be a risk factor for cardiac disease, and CSA can be a consequence of cardiac disease in populations with sleep-disordered breathing. Primary outcomes were quite different (for instance, the Apnea Positive Pressure Long-term Efficacy Study (APPLES) trial),3 and studies that involved primary2 and secondary prevention of CVD4–8 were included. The follow-up varied substantially (6–68 months) as well as the sample sizes (n=83 to n=2717). The analysis was hampered by poor adherence with the exception of the Parra et al report.6 Taking the above limitations into account, particularly the inappropriate combination of studies as well as the rather uniform low adherence, it is difficult to draw firm conclusions regarding the value of PAP in mitigating cardiovascular risk.

Implications for practice

What can we take away from this report? First, excluding significant sleepiness in PAP RCTs may be excluding populations that would benefit from treatment. This work highlights that adequate adherence in these cohorts is a considerable clinical challenge. Second, there appears to be a differential response to patient-centred measures of improvement (sleepiness and quality of life) versus improvement in cardiac outcomes. The later may require more complete treatment (ie, adherence throughout the entire sleep period) and particularly treatment during rapid eye movement sleep. Further, carefully designed RCTs are needed to address the limitations noted above before we abandon PAP therapy in patients with OSA at risk or with established cardiovascular disease.

References

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
View Abstract

Footnotes

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.